LARGE B-CELL LYMPHOMA

This study tests a new treatment called cemacabtagene ansegedleucel (cema-cel) for adults with large B-cell lymphoma who have tiny amounts of cancer left after their first treatment. Participants are randomly assigned to receive either cema-cel (a type of CAR T cell therapy made …

This Phase 3 trial tests a new CAR T-cell therapy called ronde-cel, which targets two proteins (CD19 and CD20) on lymphoma cells, against the standard single-target CAR T therapy. The study involves 400 adults with large B-cell lymphoma that has returned or not responded after in…

This study tests a new treatment called CTX112 for people with B-cell blood cancers (like lymphoma or leukemia) that have come back or not responded to standard therapy. CTX112 uses CRISPR gene-editing to create donor T-cells that target and kill cancer cells. The trial involves …

This study is for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who are older, frail, or cannot receive a common chemotherapy drug called anthracycline. Researchers want to see if adding the drug epcoritamab to a gentler chemo regimen (R-miniCVP) can better co…

This early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells. The main…

This early-stage study tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have returned or not improved with standard treatments. The therapy uses a harmless virus to deliver a gene that helps the immune system attack c…

This study tests whether giving targeted radiation to large tumors before CAR-T cell therapy can help control cancer better in people with aggressive large B-cell lymphoma. About 27 participants with bulky disease (tumors at least 5 cm) will receive this combination. The goal is …

This study tests a combination of two drugs, tafasitamab and lenalidomide, in people with large B-cell lymphoma that did not fully go away after CAR-T cell therapy. The goal is to see if this treatment can shrink or eliminate the remaining cancer. About 28 adults will take part f…

This study is testing a new drug called AZD0486, either alone or with other cancer drugs, in people with certain types of blood cancers like leukemia and lymphoma. The goal is to see if the drug is safe and works against the cancer. About 408 adults will take part in this early-p…

This study tests whether the drug loncastuximab tesirine can help control large B-cell lymphoma in people who had only a partial response after CAR T-cell therapy. About 30 adults will receive the drug to see if it can turn a partial response into a complete remission. The goal i…

This study tests whether giving an extra antibody drug (mosunetuzumab or glofitamab) after CAR-T cell therapy can improve results for people with aggressive large B-cell lymphoma that has come back or not responded to prior treatments. About 42 participants will receive the combi…

This trial tests a new CAR T-cell therapy called WZTL-002 in 60 people with large B-cell lymphoma that has returned or not responded to standard chemotherapy. Participants receive their own modified immune cells to attack the cancer, and doctors will check how many achieve comple…

This study tests whether combining two drugs, epcoritamab and loncastuximab tesirine, is safe and effective for people with large B-cell lymphoma that has come back or stopped responding to treatment. About 26 adults will receive the drug combination, and researchers will monitor…

This early-phase study tests whether it is safe and possible to collect a patient's own blood stem cells and give them together with CAR-T cell therapy for people with blood cancers that have come back or not responded to treatment. About 20 adults aged 18 to 85 with certain type…

This study tests whether a shorter course of chemotherapy (2 cycles instead of 6) followed by a new targeted drug called AZD0486 works better and is safer than the standard 6-cycle chemo for elderly or frail patients newly diagnosed with large B-cell lymphoma. About 420 participa…

This study tests whether the drug emapalumab can prevent severe cytokine release syndrome (CRS), a common and serious side effect of CAR-T cell therapy, in adults with certain types of non-Hodgkin lymphoma that have come back or not responded to treatment. About 28 participants w…

This study tests a new treatment called ronde-cel for people with aggressive B-cell lymphoma that has come back or not improved after at least two prior therapies. The treatment uses a patient's own immune cells, modified to target two different markers on cancer cells. The goal …

This study tests whether a CAR T-cell therapy called liso-cel can prevent large B-cell lymphoma from returning in patients who still have traces of cancer DNA after standard treatment. About 10 adults who are in remission but test positive for lymphoma DNA will receive their own …

This study offers a special CAR T-cell treatment called axicabtagene ciloleucel to people with large B-cell or follicular lymphoma whose commercial batch didn't pass quality checks. Participants must meet safety criteria and have no other good options. The goal is to provide acce…

This study is testing whether a second dose of a CAR T-cell therapy called Axi-Cel is safe for people with a type of blood cancer called large B-cell lymphoma that is hard to treat. About 20 adults who have already had standard CAR T treatment but are at high risk of their cancer…

This early-stage study tests an experimental drug (UB-VV400) alone and with rapamycin in adults with aggressive B-cell lymphoma that has returned or not responded to treatment. About 70 participants will receive the therapy to find the safest dose and check for side effects. The …

This early-phase study tests a drug called NT-I7 (a long-acting immune booster) given after standard CAR T-cell therapy for people with relapsed or hard-to-treat large B-cell lymphoma. The goal is to see if NT-I7 is safe and can help CAR T-cells grow and last longer in the body, …

This study reviews medical records from about 250 adults with large B-cell lymphoma who received the drug Glofitamab through a special access program in France. Researchers want to see how well the drug controls the cancer and what side effects occur, especially in patients whose…

This study tests a combination of three drugs (glofitamab, a PD-1 inhibitor, and lenalidomide) in 24 people with a type of large B-cell lymphoma that has returned or not responded to treatment and has a specific gene change (TP53). The goal is to see if this combination can shrin…

This early study looks at whether a supplement called beta-hydroxybutyrate (BHB) is safe and tolerable for people with large B-cell lymphoma who are receiving standard CAR T-cell therapy. Only 5 adults will take the supplement by mouth for a short time. Researchers will also chec…

This study aims to find clues that predict how well CAR-T therapy works for people with relapsed or hard-to-treat large B-cell lymphoma. Researchers will look at patient health records, tumor features, and immune system changes in 80 participants. The goal is not to test a new tr…

This study tests a new training program called Hematolo-GIST that helps doctors communicate more clearly with patients who have large B-cell lymphoma. The goal is to improve how doctors discuss the diagnosis and plan future care. About 48 people, including doctors and patients, w…